Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post on LinkedIn:
“Tumor-agnostic biomarker-directed FDA approvals have expanded the patient population that qualify for targeted therapies, but challenges remain on how to translate these advancements into improved patient outcomes. Dr. Vivek Subbiah has been an important voice in this area, and he joins Dr. Theo Nicolaides to discuss how to move the field forward. Please join this online discussion next Tuesday, Sept 16th!”
Read more about FDA approvals.